TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of “Hold” by Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX) has been given an average rating of “Hold” by the six ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $6.00.

TCRX has been the subject of several research analyst reports. Wall Street Zen cut shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Wedbush upped their target price on shares of TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Thursday, March 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Tuesday, April 21st.

TScan Therapeutics Stock Performance

Shares of NASDAQ:TCRX opened at $1.08 on Friday. TScan Therapeutics has a 52 week low of $0.88 and a 52 week high of $2.57. The company’s 50 day moving average is $1.10 and its two-hundred day moving average is $1.07. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.34. The company has a market cap of $70.58 million, a PE ratio of -1.12 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, meeting analysts’ consensus estimates of ($0.22). TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 91.94%. The company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $2.50 million. Equities analysts predict that TScan Therapeutics will post -1.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of TScan Therapeutics by 7.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company’s stock valued at $4,219,000 after buying an additional 168,540 shares in the last quarter. Aberdeen Group plc boosted its stake in TScan Therapeutics by 31.8% during the 4th quarter. Aberdeen Group plc now owns 1,785,241 shares of the company’s stock worth $1,785,000 after purchasing an additional 430,421 shares during the period. Renaissance Technologies LLC boosted its stake in TScan Therapeutics by 19.6% during the 1st quarter. Renaissance Technologies LLC now owns 1,364,783 shares of the company’s stock worth $1,378,000 after purchasing an additional 223,714 shares during the period. Two Sigma Investments LP boosted its stake in TScan Therapeutics by 14.9% during the 3rd quarter. Two Sigma Investments LP now owns 419,404 shares of the company’s stock worth $763,000 after purchasing an additional 54,370 shares during the period. Finally, Citadel Advisors LLC boosted its stake in TScan Therapeutics by 78.4% during the 3rd quarter. Citadel Advisors LLC now owns 390,747 shares of the company’s stock worth $711,000 after purchasing an additional 171,760 shares during the period. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.